Radiotherapy Reduces Need for Anti-VEGF in Study
Oraya Therapeutics, Inc. issued positive results from the Intrepid trial. Stereotactic radiotherapy reduced the need for anti-VEGF injections by 54% for the patient sub-group characterized by the presence of significant fluid and smaller lesion size. For the full 230 patient cohort it reduced the frequency by 32%. The total procedure time is typically less than 20 minutes. Some patients will be able to go as much as one year without further treatment. The IRay system will be launched shortly in the UK.